"The required re-rate arguments already at least partially met with swiftly growing Striate revenues. Investors need to do at least a little forward extrapolation."
You ask too much from dumb Aussie retail.
I mentioned the moaning and groaning that would set in. The sp has run up sharply the last two weeks and clearly needs some rest, yet people complain.
Getting back to ATI partnerships, PA did mention to me that J&J have first dibs on the data while Orthocell retain the right to partner up with whomever they choose. The fact that J&J havent gone ahead today means little. Legalities of partnerships aside, that take a long time, it's clear Orthocell are following the same formula to market they used for Striate+, which they're also utilising for Remplir.
This is by far and away the easiest buy & hold microcap I have seen in a long time.
OCC Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
(20min delay)